First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.
Work
Year: 2022
Type: article
Source: Journal of Clinical Oncology
Institutions Centre Hospitalier Régional Universitaire de Brest, National Cancer Center Hospital East, Sungkyunkwan University, Samsung Medical Center, Cornell University +19 more
Cites:
Cited by: 19
Related to: 10
FWCI: 6.197
Citation percentile (by year/subfield): 87.3
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: closed